Sunday 18 October 2026
Export ACIU’s income statement to Excel — free account
AC Immune
ACIU Healthcare Biotechnology
AC Immune’s revenue for fiscal 2025 (year ended December 2025) was $4.3 million, down 86.1% from fiscal 2024. In the quarter to June 2026, revenue grew 29.7%, EPS grew 9.52% and free cash flow grew 4.66%, each against the same quarter a year earlier.
2.39
0.06
−2.45%
Follow ACIU
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
2 | 5 | — | — | — | 2 | 7 | 3 | 1 | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 12.72 | 0.00 | 0.00 | 37.17 |
Altman Z-Score |
(3.99) | (1.29) | 7.71 | 3.29 | — | 8.52 | 14.99 | 17.55 | 28.34 | 28.63 |
P/S ratio |
73.36 | 8.66 | 61.84 | 28.75 | — | 22.59 | 5.38 | 79.45 | 37.02 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(11.78) | (3.71) | 4.00 | 7.40 | — | 12.17 | 16.88 | 12.14 | 11.10 | 15.56 |
P/FCF ratio |
0.00 | 3.63 | 0.00 | 0.00 | — | 0.00 | 11.21 | 0.00 | 0.00 | 16.71 |
Beneish M-Score |
1.01 | (6.56) | 9.12 | — | — | 1.77 | 11.17 | (3.06) | (1.65) | (1.38) |
P/Operating CF |
(17.89) | 48.36 | (23.04) | (9.74) | — | (18.75) | (44.92) | (47.86) | 107.08 | 494.37 |
P/B ratio |
5.84 | 2.11 | 2.22 | 1.04 | — | 1.62 | 2.19 | 3.22 | 6.42 | 4.30 |
Price to Tangible BV |
0.00 | 3.83 | 3.24 | 1.49 | — | 1.62 | 2.19 | 3.22 | 6.42 | 4.30 |
EV/Sales |
48.34 | 2.69 | 44.36 | 9.13 | — | 8.09 | 2.81 | 53.60 | 30.90 | 0.00 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 6.80 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(2.49) | 1.12 | (4.23) | (0.76) | — | (2.10) | 5.64 | (8.75) | (28.33) | 12.15 |
EV/FCF |
(2.46) | 1.13 | (4.18) | (0.75) | — | (2.04) | 5.84 | (8.39) | (26.19) | 12.52 |
Quick Ratio |
0.98 | 1.65 | 8.73 | 10.71 | 9.92 | 16.14 | 16.50 | 14.29 | 12.85 | 15.39 |
Current Ratio |
1.02 | 1.71 | 9.22 | 11.16 | 10.12 | 16.53 | 16.72 | 14.75 | 13.28 | 15.61 |
Net Debt/EBITDA |
1.37 | 3.30 | 2.00 | 1.79 | 2.59 | 3.81 | (6.29) | 3.83 | 5.65 | 14.95 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.22% | 0.26% | 0.30% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.02 | 0.13 | 0.08 | 0.02 | 0.00 | 0.06 | 0.45 | 0.04 | 0.14 | 0.20 |
Operating CF/Net income |
0.98 | (1.29) | 1.11 | 1.04 | 0.90 | 0.96 | 1.22 | 0.87 | 0.84 | 0.80 |
Capex/Depreciation |
(0.35) | (0.27) | (0.36) | (0.53) | (1.10) | (0.83) | (1.48) | (1.93) | (3.11) | (3.23) |
Interest Coverage |
(362.98) | (393.75) | (304.75) | (199.57) | (135.98) | (332.86) | 11.30 | (166.26) | (5.56) | (40.85) |
| (93.59%) | (37.74%) | (33.94%) | (34.41%) | (33.03%) | (26.21%) | 20.07% | (34.69%) | (20.39%) | (6.59%) | |
| (37.92%) | (24.83%) | (30.32%) | (30.84%) | (29.54%) | (23.76%) | 18.22% | (31.09%) | (18.34%) | (5.96%) | |
ROIC |
0.00% | 0.00% | (58.19%) | (95.42%) | (146.26%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(1,753.26%) | (68.99%) | (47.18%) | (58.54%) | (38.88%) | (27.87%) | 16.28% | (27.82%) | (21.62%) | (4.86%) |
Average Days of Receivables |
99.90 | 14.76 | 380.32 | 36.36 | 0.00 | 7.78 | 1.00 | 22.07 | 16.54 | 8.13 |
Research and Development Expense of Revenue |
1,579.52% | 229.12% | 368.94% | 1,533.31% | 0.00% | 385.50% | 45.42% | 615.47% | 161.26% | 111.03% |
Selling, General and Administrative Expense of Revenue |
450.44% | 63.20% | 103.41% | 401.24% | 0.00% | 120.26% | 14.46% | 173.30% | 50.02% | 34.01% |
Intangible Assets out of Total Assets |
0.33 | 0.22 | 0.28 | 0.27 | 0.19 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
123.03% | 20.03% | 29.49% | 84.62% | 0.00% | 26.49% | 2.55% | 35.00% | 7.80% | 5.67% |
Graham Net Nets |
(0.05) | 0.23 | 0.29 | 0.63 | — | 0.60 | 0.45 | 0.30 | 0.15 | 0.23 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 7.65 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(26.75%) | (21.11%) | (15.14%) | (40.72%) | — | (17.79%) | 7.86% | (8.89%) | (3.60%) | 2.69% |
Free Cash Flow Yield |
(26.76%) | 27.54% | (17.16%) | (42.45%) | — | (17.55%) | 8.92% | (8.04%) | (3.19%) | 5.98% |
Revenue per Share |
0.04 | 0.31 | 0.19 | 0.05 | 0.00 | 0.23 | 1.58 | 0.12 | 0.36 | 0.47 |
Operating CF per Share |
(0.83) | 0.75 | (0.79) | (0.92) | (0.96) | (0.88) | 0.79 | (0.73) | (0.39) | (0.11) |
Capex per Share |
(0.01) | (0.01) | (0.01) | (0.02) | (0.04) | (0.02) | (0.03) | (0.03) | (0.03) | (0.02) |
Free Cash Flow per Share |
(0.84) | 0.74 | (0.80) | (0.94) | (1.00) | (0.91) | 0.76 | (0.76) | (0.43) | (0.13) |
Cash per Share |
1.10 | 1.89 | 1.36 | 1.54 | 2.89 | 3.35 | 4.11 | 3.08 | 2.21 | 3.08 |
Shareholders Equity per Share |
0.54 | 1.28 | 2.11 | 2.12 | 3.39 | 3.20 | 3.88 | 2.94 | 2.08 | 2.89 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.54 | 1.28 | 2.11 | 2.12 | 3.39 | 3.20 | 3.88 | 2.94 | 2.08 | 2.89 |
Free Cash Flow |
(84.67) | 74.14 | (68.18) | (78.39) | (74.75) | (65.23) | 53.68 | (46.96) | (24.29) | (6.65) |
Working Capital |
2.45 | 80.83 | 124.29 | 122.20 | 199.79 | 232.25 | 277.05 | 183.87 | 121.73 | 147.19 |
Capital Expenditures |
(1.07) | (0.65) | (0.89) | (1.30) | (2.88) | (1.75) | (1.90) | (1.90) | (1.83) | (0.91) |
Net Current Asset Value |
(15.26) | 60.60 | 114.71 | 116.47 | 189.47 | 222.39 | 267.69 | 177.89 | 116.22 | 143.33 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 7.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.25 | 0.02 | 0.05 | 0.31 | 0.00 | 0.11 | 0.02 | 0.26 | 0.09 | 0.04 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 13.42 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
1.26 | 0.82 | 0.66 | 0.55 | 0.47 | 0.45 | 0.33 | 0.29 | 0.25 | 0.25 |
Cash ROIC |
(51.47%) | 23.50% | (23.21%) | (25.66%) | (15.88%) | (13.86%) | 9.50% | (12.60%) | (9.89%) | (2.22%) |
Accounts Receivable Turnover |
3.54 | 3.37 | 1.87 | 9.38 | 0.00 | 50.11 | 297.72 | 10.68 | 28.24 | 58.56 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | — | 0.00 | — | — | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | — | 0.00 | — | — | — | — | — |
Average Receivables |
1.22 | 9.22 | 8.79 | 0.44 | 0.41 | 0.33 | 0.38 | 0.69 | 0.73 | 0.40 |
Average Payables |
2.76 | 2.44 | 1.42 | 1.58 | 2.26 | 1.24 | 1.08 | 1.57 | 2.60 | 2.94 |
Average Assets |
224.24 | 232.97 | 199.24 | 240.44 | 270.34 | 277.92 | 251.08 | 167.56 | 146.33 | 120.84 |
Average Common Equity |
90.85 | 153.23 | 178.01 | 215.45 | 241.82 | 252.02 | 227.91 | 150.17 | 131.65 | 109.25 |
Columns are period end dates